Haem oxygenase-I and cardiovascular disease: mechanisms and therapeutic potential

被引:52
|
作者
Chan, Kim H. [3 ,4 ]
Ng, Martin K. C. [3 ,4 ]
Stocker, Roland [1 ,2 ]
机构
[1] Univ Sydney, Sch Med Sci Pathol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia
[3] Heart Res Inst, Newtown, NSW 2042, Australia
[4] Royal Prince Alfred Hosp, Dept Cardiol, Camperdown, NSW 2050, Australia
基金
英国医学研究理事会;
关键词
angiogenesis; atherosclerosis; bilirubin; cardiovascular disease; haem oxygenase-1 (HO-1); vascular repair; CORONARY-ARTERY-DISEASE; GENE PROMOTER POLYMORPHISM; SOLUBLE GUANYLATE-CYCLASE; MUSCLE-CELL PROLIFERATION; HUMAN ENDOTHELIAL-CELLS; GROWTH-FACTOR SYNTHESIS; CARBON-MONOXIDE; NITRIC-OXIDE; OXIDATIVE STRESS; SERUM BILIRUBIN;
D O I
10.1042/CS20100508
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cardiovascular disease remains the leading cause of death worldwide. Despite progress in management, there remain a significant number of patients who are not eligible for current treatment options. Traditionally, HO-1 (haem oxygenase-1), one of two isoenzymes that initiate haem catabolism, was thought to only play a metabolic role. However, HO-I is now recognized to have additional protective activities in states of heightened noxious stimuli or stress such as acute coronary syndromes. The present review article provides an overview of the mode of action of HO-I in vascular protection, with particular emphasis on its atheroprotective, anti-inflammatory and antioxidative properties, as well as its role in vascular repair. Furthermore, we present evidence for the protective effects of HO-I in CVD (cardiovascular disease) in both animal and human studies. Given its potential in vascular protection and repair, strategies aimed at inducing HO-I emerge as a novel and alternative therapeutic target in the management of CVD.
引用
收藏
页码:493 / 504
页数:12
相关论文
共 50 条
  • [31] Flavonoids: Potential therapeutic agents for cardiovascular disease
    Liu, Yingxue
    Luo, Jing
    Peng, Lin
    Zhang, Qi
    Rong, Xi
    Luo, Yuhao
    Li, Jiafu
    HELIYON, 2024, 10 (12)
  • [32] Mitochondrial remodeling in cardiovascular disease: Therapeutic potential
    Kannan Balachander
    Jayaseelan Vijayashree Priyadharsini
    Arumugam Paramasivam
    Hypertension Research, 2023, 46 : 542 - 543
  • [33] Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease
    Fassett, Robert G.
    Coombes, Jeff S.
    MARINE DRUGS, 2011, 9 (03) : 447 - 465
  • [34] Emodin in cardiovascular disease: The role and therapeutic potential
    Guo, Yuanyuan
    Zhang, Rongzhen
    Li, Wenlan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Therapeutic potential of apelin and Elabela in cardiovascular disease
    Gao, Shenghan
    Chen, Hongping
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 166
  • [36] Therapeutic potential of ALKB homologs for cardiovascular disease
    Xiao, Ming-Zhu
    Liu, Jia-Ming
    Xian, Cui-Ling
    Chen, Keng-Yu
    Liu, Zhong-Qiu
    Cheng, Yuan-Yuan
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 131
  • [37] The potential of adipokines as therapeutic agents for cardiovascular disease
    Shibata, Rei
    Ohashi, Koji
    Murohara, Toyoaki
    Ouchi, Noriyuki
    CYTOKINE & GROWTH FACTOR REVIEWS, 2014, 25 (04) : 483 - 487
  • [38] Targets of Vitamin C With Therapeutic Potential for Cardiovascular Disease and Underlying Mechanisms: A Study of Network Pharmacology
    Zhu, Ning
    Huang, Bingwu
    Jiang, Wenbing
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [39] Simvastatin ameliorates established pulmonary hypertension through a heme oxygenase-I dependent pathway in rats
    Hsu, Hsao-Hsun
    Ko, Wen-Je
    Hsu, Jo-Yu
    Chen, Jin-Shing
    Lee, Yung-Chie
    Lai, I-Rue
    Chen, Chau-Fong
    RESPIRATORY RESEARCH, 2009, 10
  • [40] Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
    Siasos, G.
    Tousoulis, D.
    Kollia, C.
    Oikonomou, E.
    Siasou, Z.
    Stefanadis, C.
    Papavassiliou, A. G.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (08) : 1193 - 1209